International Archives of Allergy and Immunology
Original Paper
T Helper Lymphocyte Response to Respiratory Syncytial Virus and Its Components in Patients with Respiratory Allergy and Nonatopic ControlsShimojo N. · Katsuki T. · Tateno N. · Tomiita M. · Kohno Y.Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 13, 2007
Accepted: January 28, 2008
Published online: June 03, 2008
Issue release date: September 2008
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Abstract
Background: Respiratory syncytial virus (RSV) G protein is involved in Th2-shifted immune response, while F protein has a reverse effect on RSV infection in Th2-prone BALB/c mice. Studies on the human T cell response to F or G protein are few, and the relationship between the immune response to G protein and atopy is not known. Methods: We established CD4+ RSV-specific T cell lines (TCLs) from adult patients with respiratory allergic diseases (allergics) or nonatopic controls (controls), and examined proliferative responses and γ-interferon (IFN-γ) and interleukin 4 (IL-4) production in these TCLs upon stimulation with RSV, F or G proteins. Results: 32 and 29 RSV-specific oligoclonal TCLs were established from allergics and controls, respectively. IL-4/IFN-γ in the culture supernatant of antigen-stimulated TCLs was significantly higher in allergics than in controls (p = 0.042). IL-4/IFN-γ ratios in the culture supernatants of G-protein-reactive TCLs were significantly higher in allergics than in controls (p = 0.016), while no differences in IL-4/IFN-γ in culture supernatants of F-protein-reactive TCLs were found between allergics and controls (p = 0.787). IL-4/IFN-γ in the culture supernatants of G-protein-reactive TCLs was significantly higher than those of F-protein-reactive TCLs in allergics (p = 0.023) but not in controls (p = 0.768). Conclusion: The results suggest that the T cell response to RSV is influenced by the atopic diathesis as well as by individual RSV antigens, and that G protein may be an important antigen involved in allergy in humans.
© 2008 S. Karger AG, Basel
Related Articles:
References
-
Ogra PL: Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004;5(suppl A):S119–S126.
External Resources
- Stein RT, Sherrill D, Morgan WJ, et al: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541–545.
-
Sigurs N, Gustafsson PM, Bjarnason R, et al: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137–141.
External Resources
- Schauer U, Hoffjan S, Bittscheidt J, et al: RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J 2002;20:1277–1283.
- Wenzel SE, Gibbs RL, Lehr MV, Simoes EA: Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002;112:627–633.
-
Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus; in Fields BN, Knipe DM, Howley PM (eds): Fields’ Virology, ed 3. Philadelphia, Raven Publishers, 1996, pp 1313–1351.
- Psarras S, Papadopoulos NG, Johnston SL Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing. Paediatr Respir Rev 2004;5(suppl A):S179–S184.
- Blanco-Quiros A, Gonzalez H, Arranz E, Lapena S: Decreased interleukin-12 levels in umbilical cord blood in children who developed acute bronchiolitis. Pediatr Pulmonol 1999;28:175–180.
- Trefny P, Stricker T, Baerlocher C, Sennhauser FH: Family history of atopy and clinical course of RSV infection in ambulatory and hospitalized infants. Pediatr Pulmonol 2000;30:302–306.
- Harris J, Werling D: Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003;5:671–680.
- Alwan WH, Record FM, Openshaw PJ: Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol 1993;150:5211–5218.
- Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ: Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 1998;161:6215–6222.
- Stark JM, McDowell SA, Koenigsknecht V, et al: Genetic susceptibility to respiratory syncytial virus infection in inbred mice. J Med Virol 2002;67:92–100.
- Jackson M, Scott R: Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. J Med Virol 1996;49:161–169.
- Shimojo N, Kohno Y, Katsuki T, Hoshioka A, Honma K, Saito K, Niimi H: Diminished interferon-gamma (IFN-gamma) production by bacterial antigen-specific T cells in atopic patients. Clin Exp Immunol 1996;106:62–66.
- Ebner C, Siemann U, Najafian N, Scheiner O, Kraft D: Characterization of allergen (Bet v 1)-specific T cell lines and clones from non-allergic individuals. Int Arch Allergy Immunol 1995;107:183–185.
- Graham BS, Johnson TR, Peebles RS: Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000;48:237–247.
- de Waal L, Yuksel S, Brandenburg AH, et al: Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol 2004;78:1775–1781.
- Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJ: Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur Respir J 2002;20:376–382.
- Pala P, Message SD, Johnston SL, Openshaw PJ: Increased aeroallergen-specific interleukin-4-producing T cells in asthmatic adults. Clin Exp Allergy 2002;32:1739–1744.
- Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS: Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol 2000;164:6583–6592.
- Makela MJ, Tripp R, Dakhama A, et al: Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. J Allergy Clin Immunol 2003;112:861–869.
- Johnson TR, Graham BS: Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999;73:8485–8495.
- Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ: Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999;73:7099–7107.
- Elliott MB, Pryharski KS, Yu Q, et al: Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol 2004;78:8446–8454.
- Darville T, Yamauchi T: Respiratory syncytial virus. Pediatr Rev 1998;19:55–61.
-
Johnson TR, Parker RA, Johnson JE, Graham BS: IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 2003;174:2037–2045.
- Schwarze J, Schauer U: Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax 2004;59:517–521.
- Bont L, Versteegh J, Swelsen WT, et al: Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002;52:363–367.
- Chang J, Braciale TJ: Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med 2002;8:54–60.
Article / Publication Details
Received: August 13, 2007
Accepted: January 28, 2008
Published online: June 03, 2008
Issue release date: September 2008
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
